

## **I. AMENDMENT**

### **In the Claims:**

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-20 (Cancelled)

21. (Currently amended) A method of delivering recombinant adeno-associated virus virions to the brain of a subject suffering from a central nervous system (CNS) disorder, comprising:

(a) providing a pharmaceutical composition comprising recombinant adeno-associated virus virions, said recombinant adeno-associated virus virions encoding a therapeutic protein; and

(b) administering said composition to the brain of the subject such that ~~widespread~~ distribution of said recombinant adeno-associated virus virions over an area greater than 5 mm<sup>2</sup> is achieved ~~and the therapeutic protein is expressed at levels that provide a therapeutic effect in said subject.~~

22. (Previously presented) The method of claim 21, wherein said recombinant adeno-associated virus virions are administered using convection enhanced delivery.

23. (Previously presented) The method of claim 22, wherein said convection enhanced delivery is performed using an infusion pump.

24. (Previously presented) The method of claim 22, wherein said convection enhanced delivery is performed using an osmotic pump.

25. (Previously presented) The method of claim 21, wherein said recombinant adeno-associated virus virions are administered to the striatum.

26. (New) The method of claim 23, wherein distribution of said recombinant adeno-associated virus virions is over an area of at least 40-50 mm<sup>2</sup>.

27. (New) The method of claim 24, wherein distribution of said recombinant adeno-associated virus virions is over an area of at least 40-50 mm<sup>2</sup>.